- United States
- /
- Medical Equipment
- /
- NasdaqGS:VREX
Varex Imaging Full Year 2024 Earnings: EPS Misses Expectations
Varex Imaging (NASDAQ:VREX) Full Year 2024 Results
Key Financial Results
- Revenue: US$811.0m (down 9.2% from FY 2023).
- Net loss: US$47.7m (down by 199% from US$48.2m profit in FY 2023).
- US$1.17 loss per share (down from US$1.20 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Varex Imaging EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates.
The primary driver behind last 12 months revenue was the Medical segment contributing a total revenue of US$581.7m (72% of total revenue). Notably, cost of sales worth US$554.1m amounted to 68% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$137.8m (45% of total expenses). Explore how VREX's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 2.7% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's shares are up 13% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for Varex Imaging that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:VREX
Good value with moderate growth potential.
